Baidu
map

JAHA:FFR vs. OCT 冠状动脉病变如何选择造影术

2019-07-25 国际循环编辑部 国际循环

血流储备分数(FFR)和光学相干断层扫描术(OCT)对冠状动脉造影中病变的评估和经皮冠状动脉介入治疗的优化均有帮助。近期发表于《美国心脏协会杂志》(Journal of the American Heart Association)的一篇研究对此设计了一项前瞻性试验,比较FFR或OCT在冠状动脉病变造影中的临床价值和经济效果。

血流储备分数(FFR)和光学相干断层扫描术(OCT)对冠状动脉造影中病变的评估和经皮冠状动脉介入治疗的优化均有帮助。近期发表于《美国心脏协会杂志》(Journal of the American Heart Association)的一篇研究对此设计了一项前瞻性试验,比较FFR或OCT在冠状动脉病变造影中的临床价值和经济效果。

研究共纳入350例接受冠状动脉病变(n=446)造影的患者,将其随机分入FFR组或OCT组。FFR组中,FFR评分≤0.80的患者接受经皮冠状动脉介入治疗,目标是术后将FFR值升至0.90以上。OCT组中,狭窄区域≥75%、50%~75%狭窄区域同时最小管腔面积<2.5 mm2或斑块溃疡的患者接受经皮冠状动脉介入治疗。评估两组患者1个月和13个月时的费用、心绞痛发作频率和主要心血管不良事件情况,结果显示在研究开始1个月时提取的早期数据与对次要终点的预先分析一致。与OCT组相比,随机分入FFR组的患者在临床管理方面仅需药物治疗的比例更高(67.7% vs. 41.1%;P<0.001)、造影剂用量更少(245±137 vs. 280±129 ml;P=0.004)、造影剂诱导急性肾损伤发生比例更低(1.7% vs. 8.6%;P=0.034)。在研究开始1个月时,OCT组患者治疗的总成本与FFR组相比显著(2831±1288 vs. 4292±3844欧元/人;P<0.001),而两组主要不良心血管事件或严重心绞痛的发生情况无显著差异。

在冠状动脉病变造影的患者中,与OCT相比,FFR能显著提高仅采取药物治疗患者的治疗率。这可使患者1个月时造影剂使用剂量显著减少,显著降低造影剂诱导急性肾损伤的风险和治疗总成本。

原始出处:
Antonio Maria Leone, Francesco Burzotta, et al. Prospective Randomized Comparison of Fractional Flow Reserve vs. Optical Coherence Tomography to Guide Revascularization of Intermediate Coronary Stenoses: One‐Month Results. Journal of the American Heart Association. Originally published 23 Jul 2019.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1814306, encodeId=dbe61814306a6, content=<a href='/topic/show?id=54149498e79' target=_blank style='color:#2F92EE;'>#造影术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94987, encryptionId=54149498e79, topicName=造影术)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Jan 18 10:48:00 CST 2020, time=2020-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981114, encodeId=04ad198111488, content=<a href='/topic/show?id=a23c3088957' target=_blank style='color:#2F92EE;'>#冠状动脉病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30889, encryptionId=a23c3088957, topicName=冠状动脉病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Wed Jan 08 02:48:00 CST 2020, time=2020-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858343, encodeId=0215185834300, content=<a href='/topic/show?id=21311323521' target=_blank style='color:#2F92EE;'>#OCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13235, encryptionId=21311323521, topicName=OCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Mon Dec 02 11:48:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370579, encodeId=7a493e057998, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Jul 31 21:21:05 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268184, encodeId=6a8a126818406, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jul 27 13:48:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494123, encodeId=e7cd149412330, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Sat Jul 27 13:48:00 CST 2019, time=2019-07-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1814306, encodeId=dbe61814306a6, content=<a href='/topic/show?id=54149498e79' target=_blank style='color:#2F92EE;'>#造影术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94987, encryptionId=54149498e79, topicName=造影术)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Jan 18 10:48:00 CST 2020, time=2020-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981114, encodeId=04ad198111488, content=<a href='/topic/show?id=a23c3088957' target=_blank style='color:#2F92EE;'>#冠状动脉病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30889, encryptionId=a23c3088957, topicName=冠状动脉病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Wed Jan 08 02:48:00 CST 2020, time=2020-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858343, encodeId=0215185834300, content=<a href='/topic/show?id=21311323521' target=_blank style='color:#2F92EE;'>#OCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13235, encryptionId=21311323521, topicName=OCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Mon Dec 02 11:48:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370579, encodeId=7a493e057998, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Jul 31 21:21:05 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268184, encodeId=6a8a126818406, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jul 27 13:48:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494123, encodeId=e7cd149412330, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Sat Jul 27 13:48:00 CST 2019, time=2019-07-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1814306, encodeId=dbe61814306a6, content=<a href='/topic/show?id=54149498e79' target=_blank style='color:#2F92EE;'>#造影术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94987, encryptionId=54149498e79, topicName=造影术)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Jan 18 10:48:00 CST 2020, time=2020-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981114, encodeId=04ad198111488, content=<a href='/topic/show?id=a23c3088957' target=_blank style='color:#2F92EE;'>#冠状动脉病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30889, encryptionId=a23c3088957, topicName=冠状动脉病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Wed Jan 08 02:48:00 CST 2020, time=2020-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858343, encodeId=0215185834300, content=<a href='/topic/show?id=21311323521' target=_blank style='color:#2F92EE;'>#OCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13235, encryptionId=21311323521, topicName=OCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Mon Dec 02 11:48:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370579, encodeId=7a493e057998, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Jul 31 21:21:05 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268184, encodeId=6a8a126818406, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jul 27 13:48:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494123, encodeId=e7cd149412330, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Sat Jul 27 13:48:00 CST 2019, time=2019-07-27, status=1, ipAttribution=)]
    2019-12-02 habb
  4. [GetPortalCommentsPageByObjectIdResponse(id=1814306, encodeId=dbe61814306a6, content=<a href='/topic/show?id=54149498e79' target=_blank style='color:#2F92EE;'>#造影术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94987, encryptionId=54149498e79, topicName=造影术)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Jan 18 10:48:00 CST 2020, time=2020-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981114, encodeId=04ad198111488, content=<a href='/topic/show?id=a23c3088957' target=_blank style='color:#2F92EE;'>#冠状动脉病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30889, encryptionId=a23c3088957, topicName=冠状动脉病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Wed Jan 08 02:48:00 CST 2020, time=2020-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858343, encodeId=0215185834300, content=<a href='/topic/show?id=21311323521' target=_blank style='color:#2F92EE;'>#OCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13235, encryptionId=21311323521, topicName=OCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Mon Dec 02 11:48:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370579, encodeId=7a493e057998, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Jul 31 21:21:05 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268184, encodeId=6a8a126818406, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jul 27 13:48:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494123, encodeId=e7cd149412330, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Sat Jul 27 13:48:00 CST 2019, time=2019-07-27, status=1, ipAttribution=)]
    2019-07-31 天地飞扬

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1814306, encodeId=dbe61814306a6, content=<a href='/topic/show?id=54149498e79' target=_blank style='color:#2F92EE;'>#造影术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94987, encryptionId=54149498e79, topicName=造影术)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Jan 18 10:48:00 CST 2020, time=2020-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981114, encodeId=04ad198111488, content=<a href='/topic/show?id=a23c3088957' target=_blank style='color:#2F92EE;'>#冠状动脉病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30889, encryptionId=a23c3088957, topicName=冠状动脉病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Wed Jan 08 02:48:00 CST 2020, time=2020-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858343, encodeId=0215185834300, content=<a href='/topic/show?id=21311323521' target=_blank style='color:#2F92EE;'>#OCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13235, encryptionId=21311323521, topicName=OCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Mon Dec 02 11:48:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370579, encodeId=7a493e057998, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Jul 31 21:21:05 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268184, encodeId=6a8a126818406, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jul 27 13:48:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494123, encodeId=e7cd149412330, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Sat Jul 27 13:48:00 CST 2019, time=2019-07-27, status=1, ipAttribution=)]
    2019-07-27 zhaohui6731
  6. [GetPortalCommentsPageByObjectIdResponse(id=1814306, encodeId=dbe61814306a6, content=<a href='/topic/show?id=54149498e79' target=_blank style='color:#2F92EE;'>#造影术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94987, encryptionId=54149498e79, topicName=造影术)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Jan 18 10:48:00 CST 2020, time=2020-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981114, encodeId=04ad198111488, content=<a href='/topic/show?id=a23c3088957' target=_blank style='color:#2F92EE;'>#冠状动脉病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30889, encryptionId=a23c3088957, topicName=冠状动脉病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Wed Jan 08 02:48:00 CST 2020, time=2020-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858343, encodeId=0215185834300, content=<a href='/topic/show?id=21311323521' target=_blank style='color:#2F92EE;'>#OCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13235, encryptionId=21311323521, topicName=OCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Mon Dec 02 11:48:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370579, encodeId=7a493e057998, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Jul 31 21:21:05 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268184, encodeId=6a8a126818406, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jul 27 13:48:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494123, encodeId=e7cd149412330, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Sat Jul 27 13:48:00 CST 2019, time=2019-07-27, status=1, ipAttribution=)]
    2019-07-27 sodoo

相关资讯

Circ Cardiovasc Inte:支架置入术后的影像学和生理学评估

使用血流储备分数(FFR)或瞬时无波率进行侵入性生理评估已成为定义缺血所致冠状动脉狭窄和指导冠状动脉疾病患者进行血运重建策略的标准方法。此外,既往研究已表明,支架置入术后患者的FFR值会影响预后效果。即使造影显示支架置入成功,目标血管残留病变、支架扩张不充分或支架相关并发症如边缘剥离等,仍会造成FFR较低。临床医生如何应对上述局面,近期《循环:心血管介入杂志》(Circulation: Cardi

JAMA Intern Med:血流储备分数及血管内超声不能降低 PCI 手术死亡率

血流储备分数(FFR)及血管内超声(IVUS)是现今 PCI 治疗的两大辅助检测手段,并且其临床介入治疗的指导意义也得到了众多心脏病学家的认可。但是,近期的一项研究指出,与标准血管造影指导 PCI 相比,FFR 及 IVUS 指导的 PCI 并不能降低患者死亡率。死亡率未降该研究入组了伦敦 PCI 登记处 41688 例存在稳定型心绞痛及非 ST 段抬高心肌梗死(NSTEMI)的患者。在平均随访

Circ-Cardiovasc Int:FFR指导的搭桥手术可大幅降低死亡风险

根据《循环·心血管介入》杂志发表的研究结果,与传统冠脉造影指导的冠状动脉旁路移植术相比,血流储备分数(FFR)指导的冠状动脉旁路移植术能显著降低总死亡率或心肌梗死发生率。

Circulation:冠心病的另一种新的诊断试验——冠状动脉CT血管造影的非侵入性血流储备分数

尽管局部缺血评估具有临床重要性,但在浸润性心导管术中,获得性流量储备(FFR)仍然具有价值。虽然形态学与生理学之间有明显的联系,但仍然存在显著的差异。来源于冠状动脉CT血管造影的血流储备分数(FFRCT)是一种通过将形态学信息转化为血流动力学数据的方法来量化冠状动脉狭窄的血流动力学意义的一种新方法。

Radiology:冠状动脉CTA血流储备分数评价新方法!

本研究旨在比较基于计算流体动力学来源的冠状动脉CTA血流储备分数(FFR)(FFRCFD)和基于机器学习算法的冠状动脉CTA得到的FFR(FFRML)两种技术方法的价值,并将结果发表在Radiology上。

JACC:严重主动脉瓣狭窄和冠脉疾病患者TAVR术后的冠脉血流动力学

TAVR术后收缩期和充血冠脉血流显著增加。

Baidu
map
Baidu
map
Baidu
map